NRx Pharmaceuticals Shares Rise as FDA Completes Initial Review of Ketamine Product

The FDA has completed its initial review of NRx Pharmaceuticals' ketamine product, causing a rise in the company's shares as it advances through regulatory approval.

This Wire brief sits within Fusion42's coverage of Biotech.